The OLTRE trial (ClinicalTrials.gov number: NCT02681562) is an open-label, 'window of opportunity' Phase II controlled trial to evaluate the biological activity of olaparib in locally advanced triple-negative breast cancer compared with other subtypes of locally advanced breast cancer patients carrying germinal BRCA mutation receiving olaparib with the same treatment approach. The primary end point is to investigate the correlation between baseline gene and protein expression profile in order to identify possible predictive markers of response to olaparib. The OLTRE trial is expected to identify the surrogate markers of the biological activity of olaparib in the treatment of patients with triple-negative breast cancer.

A Phase II study of olaparib in breast cancer patients: Biological evaluation from a 'window of opportunity' trial / Roviello Giandomenico; Milani Manuela; Gobbi Angela; Dester Martina; Cappelletti Maria Rosa; Allevi Giovanni; Aguggini Sergio; Ravelli Andrea; Gussago Francesca; Cocconi Alessandra; Zanotti Laura; Senti Chiara; Strina Carla; Bottini Alberto; Generali Daniele. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - STAMPA. - 12:(2016), pp. 2189-2193. [10.2217/fon-2016-0116]

A Phase II study of olaparib in breast cancer patients: Biological evaluation from a 'window of opportunity' trial

Roviello Giandomenico;
2016

Abstract

The OLTRE trial (ClinicalTrials.gov number: NCT02681562) is an open-label, 'window of opportunity' Phase II controlled trial to evaluate the biological activity of olaparib in locally advanced triple-negative breast cancer compared with other subtypes of locally advanced breast cancer patients carrying germinal BRCA mutation receiving olaparib with the same treatment approach. The primary end point is to investigate the correlation between baseline gene and protein expression profile in order to identify possible predictive markers of response to olaparib. The OLTRE trial is expected to identify the surrogate markers of the biological activity of olaparib in the treatment of patients with triple-negative breast cancer.
2016
12
2189
2193
Roviello Giandomenico; Milani Manuela; Gobbi Angela; Dester Martina; Cappelletti Maria Rosa; Allevi Giovanni; Aguggini Sergio; Ravelli Andrea; Gussago...espandi
File in questo prodotto:
File Dimensione Formato  
Future oncology.pdf

Accesso chiuso

Dimensione 1.55 MB
Formato Adobe PDF
1.55 MB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1156789
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 8
social impact